Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LY3375880 Formulations in Healthy Subjects
NCT03913260Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of torudokimab in atopic dermatitis (AD), asthma and chronic obstructive pulmonary disease (COPD) (7 arms), sponsored by Eli Lilly and Company. Primary endpoints: Visual Analog Scale Pain Score, Maximum Concentration and 1 more. Started May 2019; status: completed.
02
Drugs
torudokimab
03
Conditions
atopic dermatitis (AD)asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03913260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913260.